Casana, a company specializing in monitoring heart health through smart toilets, has received FDA clearance for the Heart Seat, which measures heart rate and oxygen saturation (SpO2).
The Heart Seat features embedded sensors that capture key clinical measurements, including heart rate, blood pressure, and blood oxygenation, to assist medical teams with monitoring chronic conditions.
Alongside heart hate and oxygen saturation (SpO2), Casana has partnered with researchers to conduct validation studies of additional clinical measurements. The company plans to file future indications this year, including systolic and diastolic blood pressure (BP), with the target of an initial product market launch by the end of 2023.
"This clearance is a critical step on our journey to commercialize the Heart Seat,” said Casana CEO, Austin McChord. “This brings us one step closer to helping patients and healthcare providers across the US manage their health at home."
